Neuland FY26 Net Profit Rises 40%; Target Raised
Neuland Laboratories reported a 40% increase in FY26 net profit to ₹363.1 crore, supported by a 37.1% rise in revenue to ₹2,053.1 crore. Q4FY26 saw significant growth with total income reaching ₹788.7 crore and EBITDA margins expanding to 40.5%. Goldman Sachs maintained a Buy rating, raising the target price to ₹19,550, and expects a 20%+ topline CAGR over FY26–28. The Board recommended a final dividend of ₹34 per share. Management highlighted strong visibility from the existing pipeline and ongoing investments in peptide facilities.
*this image is generated using AI for illustrative purposes only.
Neuland Laboratories reported a strong financial performance for the year ended March 31, 2026, with consolidated net profit rising 40% to ₹363.1 crore from ₹259.4 crore in the prior year. Revenue from operations grew to ₹2,053.1 crore compared to ₹1,497.3 crore in FY25. The Board of Directors, at their meeting held on May 12, 2026, approved the audited standalone and consolidated financial results under Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The company subsequently published a newspaper advertisement regarding the financial results for the quarter and year ended March 31, 2026, in Financial Express and Nava Telangana on May 13, 2026, pursuant to Regulation 47 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
Analyst View: Goldman Sachs Raises Target Price
Goldman Sachs has maintained a Buy rating on Neuland Laboratories while raising its target price to ₹19,550, following the company's strong quarterly results. The brokerage cited a significant Q4 beat driven by robust Contract Development and Manufacturing Organisation (CDMO) performance. Goldman Sachs also highlighted EBITDA margins of 40%, supported by a superior product mix and operating leverage, as a key positive. The firm expects a 20%+ topline CAGR over FY26–28, reflecting confidence in the company's pipeline progress and business outlook. Additionally, Goldman Sachs revised its EPS estimates for FY27–29 upward by up to 8%, underpinned by improved pipeline visibility.
| Parameter: | Details |
|---|---|
| Rating: | Buy |
| Target Price: | ₹19,550 |
| Q4 EBITDA Margin: | 40% |
| Topline CAGR Expectation (FY26–28): | 20%+ |
| EPS Estimate Revision (FY27–29): | Up to 8% upward |
Consolidated Financial Performance
The company reported significant growth across key financial metrics on a consolidated basis for FY26. Total consolidated income reached ₹2,053.1 crore compared to ₹1,497.3 crore in FY25. Profit before tax (excluding exceptional items) stood at ₹488.9 crore for FY26 versus ₹269.9 crore in FY25. The prior year's profit before tax of ₹346.3 crore included an exceptional item of ₹76.4 crore arising from the transfer of an investment property in Nanakramguda, Hyderabad.
The following table summarises the consolidated financial results:
| Metric: | FY26 (Audited) | FY25 (Audited) |
|---|---|---|
| Revenue from Operations: | ₹2,02,298.54 lakhs | ₹1,47,683.73 lakhs |
| Other Income: | ₹3,016.62 lakhs | ₹2,050.93 lakhs |
| Total Income: | ₹2,05,315.16 lakhs | ₹1,49,734.66 lakhs |
| Total Expenses: | ₹1,56,417.45 lakhs | ₹1,22,742.12 lakhs |
| Profit Before Exceptional Item & Tax: | ₹48,897.71 lakhs | ₹26,992.54 lakhs |
| Profit Before Tax: | ₹48,897.71 lakhs | ₹34,632.90 lakhs |
| Net Profit: | ₹36,399.84 lakhs | ₹26,010.81 lakhs |
| Total Comprehensive Income: | ₹36,506.25 lakhs | ₹26,006.33 lakhs |
| Basic & Diluted EPS (₹10 each): | ₹283.71 | ₹202.74 |
Quarterly Performance Highlights
Neuland Laboratories delivered a sharp acceleration in profitability during Q4FY26. Total Income for the quarter stood at ₹788.7 crore, up 134.90% year-on-year from ₹335.8 crore in Q4FY25. Q4 EBITDA stood at ₹319.4 crore versus ₹58.2 crore in the prior-year quarter, with EBITDA margin expanding to 40.50% from 17.30% in Q4FY25. Working capital days of sale stood at 137 days in Q4FY26 as against 145 days in Q3FY26, mainly on account of a decrease in inventory.
The following table presents the quarterly financial summary:
| Particulars (₹ crore): | Q4FY26 | Q4FY25 | YoY (%) | Q3FY26 | QoQ (%) |
|---|---|---|---|---|---|
| Total Income: | 788.7 | 335.8 | 134.90% | 447.8 | 76.10% |
| EBITDA: | 319.4 | 58.2 | 448.60% | 85.0 | 275.80% |
| EBITDA Margin: | 40.50% | 17.30% | 2316 bps | 19.00% | 2151 bps |
| Profit Before Tax: | 287.0 | 39.0 | 636.60% | 54.3 | 428.90% |
| PBT Margin: | 36.40% | 11.60% | 2479 bps | 12.10% | 2430 bps |
| Profit After Tax: | 212.5 | 27.7 | 666.30% | 40.4 | 425.80% |
| PAT Margin: | 26.90% | 8.30% | 1869 bps | 9.00% | 1789 bps |
| EPS (₹): | 165.6 | 21.6 | 666.30% | 31.5 | 425.80% |
Final Dividend and AGM
The Board of Directors recommended a final dividend of ₹34/- (340%) per equity share of ₹10 each for the financial year 2025-26, subject to shareholder approval. The dividend will be paid on or after five days from the date of declaration at the 42nd Annual General Meeting (AGM), which has been scheduled for Tuesday, August 4, 2026. The record date for determining shareholders eligible to receive the final dividend has been fixed as July 24, 2026.
Management Commentary and Outlook
During the earnings conference call, management highlighted that the strong Q4 performance was driven by commercial CMS projects, which contributed over two-thirds of revenue for the quarter. Gross margin for Q4FY26 was 62.1% versus 56.3% in Q4FY25, driven largely by business mix. The company noted that quarterly performance can be uneven due to the nature of the business and is best evaluated over longer periods.
For FY26, EBITDA stood at ₹603.4 crore versus ₹342.8 crore in FY25, with an EBITDA margin of 29.4% compared to 22.9% in the previous year. Free cash flow for FY26 was negative at ₹49.4 crore, driven by higher working capital and increased capital cash outflows. Capex cash outflow for the year was ₹397.1 crore. The company reported a net debt position of negative ₹157 crore, supported by cash balances of ₹353 crore.
Management stated that the outlook for the coming years remains promising, with visible growth driven by the existing pipeline over the next 2 to 3 years. A key focus area is the investment in large-scale peptide commercial facilities, which is expected to help the company move into a more differentiated space. The new peptide facility is on track to be ready by July 2026. Regarding the long-term growth outlook, management indicated that an 18% to 20% CAGR is a fair assumption, though not necessarily linear.
Historical Stock Returns for Neuland Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.78% | +0.52% | +12.38% | -0.67% | +42.65% | +691.55% |
How quickly can Neuland Laboratories scale its new large-scale peptide commercial facility to capture meaningful market share in the $5-6 billion global peptide CDMO market, particularly given intensifying competition from larger CDMOs targeting GLP-1 therapies?
Given that Q4FY26's exceptional 40.5% EBITDA margin was driven by lumpy CMS revenue flows, what is a realistic normalized EBITDA margin range investors should expect for FY27, and which specific commercial milestones could sustain elevated margins?
With free cash flow negative at ₹49.4 crore and capex at ₹397 crore in FY26, how will Neuland fund its continued capacity expansion and peptide facility investments in FY27-28 without significantly increasing leverage or diluting equity?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
